No Substantial Preexisting B Cell Immunity Against SARS-CoV-2 in Healthy Adults

Overview

Journal iScience

Publisher Cell Press

Date 2022 Feb 28

PMID 35224466

Authors

Meryem Seda Ercanoglu

Lutz Gieselmann

Sabrina Dahling

Nareshkumar Poopalasingam

Susanne Detmer

Manuel Koch

Michael Korenkov

Sandro Halwe

Michael Kluver

Veronica Di Cristanziano

Hanna Janicki

Maike Schlotz

Johanna Worczinski

Birgit Gathof

Henning Gruell

Matthias Zehner

Stephan Becker

Kanika Vanshylla

Christoph Kreer

Florian Klein

Affiliations

Soon will be listed here.

Abstract

Preexisting immunity against SARS-CoV-2 may have critical implications for our understanding of COVID-19 susceptibility and severity. The presence and clinical relevance of a preexisting B cell immunity remain to be fully elucidated. Here, we provide a detailed analysis of the B cell immunity to SARS-CoV-2 in unexposed individuals. To this end, we extensively investigated SARS-CoV-2 humoral immunity in 150 adults sampled pre-pandemically. Comprehensive screening of donor plasma and purified IgG samples for binding and neutralization in various functional assays revealed no substantial activity against SARS-CoV-2 but broad reactivity to endemic betacoronaviruses. Moreover, we analyzed antibody sequences of 8,174 putatively SARS-CoV-2-reactive B cells at a single cell level and generated and tested 158 monoclonal antibodies. None of these antibodies displayed relevant binding or neutralizing activity against SARS-CoV-2. Taken together, our results show no evidence of competent preexisting antibody and B cell immunity against SARS-CoV-2 in unexposed adults.

Citing Articles

Human coronavirus OC43-elicited CD4 T cells protect against SARS-CoV-2 in HLA transgenic mice.

Alves R, Timis J, Miller R, Valentine K, Pinto P, Gonzalez A Nat Commun. 2024; 15(1):787.

PMID: 38278784 PMC: 10817949. DOI: 10.1038/s41467-024-45043-2.

Pre-pandemic SARS-CoV-2-specific IFN-γ and antibody responses were low in Ugandan samples and significantly reduced in HIV-positive specimens.

Nantambi H, Sembera J, Ankunda V, Ssali I, Kalyebi A, Oluka G Front Immunol. 2023; 14:1148877.

PMID: 37153598 PMC: 10154590. DOI: 10.3389/fimmu.2023.1148877.

Long-term adaptive response in COVID-19 vaccine recipients and the effect of a booster dose.

Perico L, Todeschini M, Casiraghi F, Mister M, Pezzotta A, Peracchi T Front Immunol. 2023; 14:1123158.

PMID: 36926327 PMC: 10011096. DOI: 10.3389/fimmu.2023.1123158.

Antibody-mediated neutralization of SARS-CoV-2.

Gruell H, Vanshylla K, Weber T, Barnes C, Kreer C, Klein F Immunity. 2022; 55(6):925-944.

PMID: 35623355 PMC: 9118976. DOI: 10.1016/j.immuni.2022.05.005.

References

Schommers P, Gruell H, Abernathy M, Tran M, Dingens A, Gristick H . Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. Cell. 2020; 180(3):471-489.e22. PMC: 7042716. DOI: 10.1016/j.cell.2020.01.010. View

Grifoni A, Weiskopf D, Ramirez S, Mateus J, Dan J, Rydyznski Moderbacher C . Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020; 181(7):1489-1501.e15. PMC: 7237901. DOI: 10.1016/j.cell.2020.05.015. View

Arvin A, Fink K, Schmid M, Cathcart A, Spreafico R, Havenar-Daughton C . A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature. 2020; 584(7821):353-363. DOI: 10.1038/s41586-020-2538-8. View

von Boehmer L, Liu C, Ackerman S, Gitlin A, Wang Q, Gazumyan A . Sequencing and cloning of antigen-specific antibodies from mouse memory B cells. Nat Protoc. 2016; 11(10):1908-1923. DOI: 10.1038/nprot.2016.102. View

Imkeller K, Wardemann H . Assessing human B cell repertoire diversity and convergence. Immunol Rev. 2018; 284(1):51-66. DOI: 10.1111/imr.12670. View

Vanshylla K, Di Cristanziano V, Kleipass F, Dewald F, Schommers P, Gieselmann L . Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. Cell Host Microbe. 2021; 29(6):917-929.e4. PMC: 8090990. DOI: 10.1016/j.chom.2021.04.015. View

Brouwer P, Caniels T, van der Straten K, Snitselaar J, Aldon Y, Bangaru S . Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020; 369(6504):643-650. PMC: 7299281. DOI: 10.1126/science.abc5902. View

Robbiani D, Gaebler C, Muecksch F, Lorenzi J, Wang Z, Cho A . Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020; 584(7821):437-442. PMC: 7442695. DOI: 10.1038/s41586-020-2456-9. View

Chiu S, Chan K, Chu K, Kwan S, Guan Y, Poon L . Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China. Clin Infect Dis. 2005; 40(12):1721-9. PMC: 7107956. DOI: 10.1086/430301. View

10.

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

11.

Yuan M, Liu H, Wu N, Lee C, Zhu X, Zhao F . Structural basis of a shared antibody response to SARS-CoV-2. Science. 2020; 369(6507):1119-1123. PMC: 7402627. DOI: 10.1126/science.abd2321. View

12.

Bert N, Tan A, Kunasegaran K, Tham C, Hafezi M, Chia A . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020; 584(7821):457-462. DOI: 10.1038/s41586-020-2550-z. View

13.

Sette A, Crotty S . Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021; 184(4):861-880. PMC: 7803150. DOI: 10.1016/j.cell.2021.01.007. View

14.

Shi R, Shan C, Duan X, Chen Z, Liu P, Song J . A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020; 584(7819):120-124. DOI: 10.1038/s41586-020-2381-y. View

15.

Ng K, Faulkner N, Cornish G, Rosa A, Harvey R, Hussain S . Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020; 370(6522):1339-1343. PMC: 7857411. DOI: 10.1126/science.abe1107. View

16.

Sagar M, Reifler K, Rossi M, Miller N, Sinha P, White L . Recent endemic coronavirus infection is associated with less-severe COVID-19. J Clin Invest. 2020; 131(1). PMC: 7773342. DOI: 10.1172/JCI143380. View

17.

Zost S, Gilchuk P, Chen R, Case J, Reidy J, Trivette A . Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med. 2020; 26(9):1422-1427. PMC: 8194108. DOI: 10.1038/s41591-020-0998-x. View

18.

Khurana S, Loving C, Manischewitz J, King L, Gauger P, Henningson J . Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med. 2013; 5(200):200ra114. DOI: 10.1126/scitranslmed.3006366. View

19.

Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L . Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. Cell. 2020; 182(1):73-84.e16. PMC: 7231725. DOI: 10.1016/j.cell.2020.05.025. View

20.

Niu X, Li S, Li P, Pan W, Wang Q, Feng Y . Longitudinal Analysis of T and B Cell Receptor Repertoire Transcripts Reveal Dynamic Immune Response in COVID-19 Patients. Front Immunol. 2020; 11:582010. PMC: 7561365. DOI: 10.3389/fimmu.2020.582010. View